UK-based QuantuMDx bags £15M funding to develop its Q-POC device that transforms PCR testing

With its headquarters in Newcastle above Tyne, QuantuMDx is committed to providing a global capability to control disease and reduce suffering. Today, the company has invested £ 15 million in funding from the Vita Spring IVD Fund, LP, a Hong Kong-based independent company that aims to grow rapidly with high-quality medical companies.

Development of Q-POC platform

QuantuMDx will use the fund’s money to increase development and improve the Q-POC level to increase its efficiency. In addition, the company plans to expand the Q-POC testing program, increase the number of sexually transmitted infections (STIs), and HPV, among others, in SARS testing. -CoV-2 is available.

The company Q-POC machine is an independent PCR machine. The fastest, hardest molecular testing software is provided as needed and rewards are given within about 30 minutes. A full lab is integrated into one easy-to-use, inexpensive machine. It is designed to be used in many organizations such as hospitals, clinics, clinics, and laboratory tests to get accurate PCR results if necessary.

Jonathan O’Halloran, CEO of QuantuMDx, said: “I am pleased to announce today the same amount that will allow us to expand the Q-POC ™ platform, as our software is one of the new platforms. Best of all, mole. Storage devices on the market. We are developing competent and effective solutions for the diagnosis and treatment of diseases so we are also looking forward to having a healthy relationship.

James Yan, Vita Spring Partner, said: “We are excited to invest in QuantMDx, which has state-of-the-art technology to meet the growing needs and growth needs of global security analysis.

Enters agreement with Sansure

QuantuMDx and Sansure Biotech Inc. entered into under the terms of the Employment Agreement. The in the vitro test solution is expected to be launched in Changsha, Hunan province, China in 2008, with more than 1,500 employees and most of the factories. The deal allows QuantuMDx to rapidly accelerate the Q-POC industry through loans with an experienced partner in China and other parts of Southeast Asia. And again, QuantuMDx offers the ability to customize production and add Q-POC tests.

Dr. Keya Zhang, Head of Business Policy at Sansure, said: “We are pleased with the capabilities of the QuantMDx and Q-POC ikwata platform. QuantuMDx’s first exam, the SARS-CoV 2 Q-POC exam, has been tried and tested for more breaks to is very effective, so QuantuMDx is important for Assurance and its four prospects for future improvement.

Translate »